155 related articles for article (PubMed ID: 9661027)
1. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM
Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027
[TBL] [Abstract][Full Text] [Related]
2. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.
Kiriyama A; Fujita K; Takemura S; Kuramoto H; Kiso Y; Takada K
Biopharm Drug Dispos; 1994 Oct; 15(7):617-26. PubMed ID: 7849237
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor.
Kiriyama A; Nishiura T; Yamaji H; Takada K
Biopharm Drug Dispos; 1999 May; 20(4):199-205. PubMed ID: 10440795
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Apr; 14(3):199-207. PubMed ID: 8490108
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kisanuki S; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Nov; 14(8):697-707. PubMed ID: 8305629
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Humphrey RW; Wyvill KM; Nguyen BY; Shay LE; Kohler DR; Steinberg SM; Ueno T; Fukasawa T; Shintani M; Hayashi H; Mitsuya H; Yarchoan R
Antiviral Res; 1999 Feb; 41(1):21-33. PubMed ID: 10321576
[TBL] [Abstract][Full Text] [Related]
7. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
Neville K; Parise RA; Thompson P; Aleksic A; Egorin MJ; Balis FM; McGuffey L; McCully C; Berg SL; Blaney SM
Clin Cancer Res; 2004 Apr; 10(7):2525-9. PubMed ID: 15073132
[TBL] [Abstract][Full Text] [Related]
8. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent.
Sugahara M; Kiriyama A; Hamada Y; Kiso Y; Takada K
Biopharm Drug Dispos; 1995 May; 16(4):269-77. PubMed ID: 7548776
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
[TBL] [Abstract][Full Text] [Related]
10. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
12. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
Kiriyama A; Sugahara M; Yoshikawa Y; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Mar; 17(2):125-34. PubMed ID: 8907719
[TBL] [Abstract][Full Text] [Related]
13. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.
Mueller BU; Lewis LL; Yuen GJ; Farley M; Keller A; Church JA; Goldsmith JC; Venzon DJ; Rubin M; Pizzo PA; Balis FM
Antimicrob Agents Chemother; 1998 Dec; 42(12):3187-92. PubMed ID: 9835513
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
Kiriyama A; Nishiura T; Yamaji H; Takada K
Antimicrob Agents Chemother; 1999 Mar; 43(3):549-56. PubMed ID: 10049266
[TBL] [Abstract][Full Text] [Related]
15. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP; Mitsuya H
Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
[TBL] [Abstract][Full Text] [Related]
16. The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
Widemann BC; Balis FM; Godwin KS; McCully C; Adamson PC
Cancer Chemother Pharmacol; 1999; 44(6):439-43. PubMed ID: 10550563
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.
Reedijk M; Boucher CA; van Bommel T; Ho DD; Tzeng TB; Sereni D; Veyssier P; Jurriaans S; Granneman R; Hsu A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1559-64. PubMed ID: 7492104
[TBL] [Abstract][Full Text] [Related]
19. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
[TBL] [Abstract][Full Text] [Related]
20. Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
Yogev R; Kovacs A; Chadwick EG; Homans JD; Lou Y; Symonds WT
Antimicrob Agents Chemother; 2005 Jan; 49(1):336-41. PubMed ID: 15616313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
